AnaptysBio (NASDAQ: ANAB) CFO sells shares to cover RSU taxes obligations

Rhea-AI Filing Summary

AnaptysBio, Inc. reported insider equity activity by its Chief Financial Officer, Dennis Mulroy. On January 7, 2026, 6,700 restricted stock units (RSUs) were settled into an equal number of common shares for no cash consideration, increasing his directly held common stock to 24,367 shares. The RSU award vests in 25% increments annually starting January 7, 2026, subject to continued service.

On January 8, 2026, he sold 2,515 common shares at $44.71 per share to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, he directly held 21,852 common shares and 20,100 RSUs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MULROY DENNIS

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		M		6,700	A	(1)	24,367	D
Common Stock	01/08/2026		S(2)		2,515	D	$44.71	21,852	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	01/07/2026		M			6,700	(3)	(3)	Common Stock	6,700	$0	20,100	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

3. The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Eric Loumeau, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AnaptysBio (ANAB) disclose for its CFO?

The filing shows CFO Dennis Mulroy had 6,700 RSUs settle into common stock on January 7, 2026, and sold 2,515 common shares on January 8, 2026 at $44.71 per share.

Why did the AnaptysBio (ANAB) CFO sell 2,515 shares?

The 2,515-share sale was made to cover tax withholding obligations tied to the vesting and settlement of RSUs and is described as a non-discretionary “sell to cover” transaction.

How many AnaptysBio (ANAB) shares does the CFO hold after these transactions?

Following the reported transactions, the CFO directly beneficially owned 21,852 shares of common stock and 20,100 RSUs.

What are the vesting terms of the AnaptysBio (ANAB) CFO’s RSUs?

The RSUs are scheduled to vest 25% annually starting on January 7, 2026 until fully vested, subject to the CFO’s continued service with the company on each vesting date.

What does each AnaptysBio (ANAB) RSU represent in this Form 4?

Each restricted stock unit (RSU) represents a contingent right to receive one share of AnaptysBio common stock upon settlement for no cash consideration.

Is the AnaptysBio (ANAB) CFO’s share sale part of a trading plan?

The filing describes the 2,515-share sale as a “sell to cover” tax transaction related to RSU vesting, and notes it does not represent a discretionary transaction by the reporting person.